What is IBRX's health score?

ImmunityBio, Inc. (IBRX) has a TradeApes health score of 42 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is IBRX's estimated fair value?

Based on our 5-year discounted cash flow model, ImmunityBio, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is IBRX undervalued or overvalued?

Our model currently rates IBRX as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for IBRX... Refresh in a moment for the full analysis.

ImmunityBio, Inc. (IBRX)

Healthcare Inconclusive inconclusive weak

$6.92

Updated: 2026-06-06

TradeApes Score

Financial Strength

40 Weak

Operating Trend

55 Mixed

Relative Value

40 Weak

Capital Allocation

20 Stressed

Risk

50 Mixed

Key Findings

+ Strong revenue growth — sales up more than 20% year over year

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

4 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.